Expression of γ-Synuclein Protein in Carcinoma of Bile Duct Tissues and Its Clinical Significance_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DAI Dongdong ¹ , LIU Guangwei ¹ , FENG Yujie ² , ZHANG Bingyuan ² , YIN Shuan ¹ ,  LU Yun. ¹

1.Department of General Surgery， Afflliated Hospital of Medical College， Qingdao University， Qingdao 266555， Shandong Province， China;;
2.Second Department of General Surgery， Afflliated Hospital of Medical College， Qingdao University， Qingdao 266003， Shandong Province， China;

Corresponding author：

LU Yun., Email: cloudylucn@126.com

Keywords：

Cholangiocarcinoma; γ-Synuclein protein; Immunhistochem

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the expression of γ-synuclein protein （SNCG） in carcinoma of bile duct and
normal bile duct tissues， and its clinical significance.
Methods 　The expressions of SNCG were detected by SP immuno-
histochemical in 60 cases of cholangiocarcinoma and 34 cases of normal bile duct tissues， and to analysis its relationship with the clinical pathological characteristics of cholangiocarcinoma.
Results 　The positive expression rate of SNCG in carcinoma of bile duct tissues was 73.33% （44/60）， which was higher than that in normal bile duct tissues （P＜0.01）. The positive expression of SNCG in carcinoma of bile duct tissues was correlated with the depth of tumor invasion and lymph node metastasis （P＜0.01）， but not related to patients’ age， gender， and the degree of tumor differentiation （P＞0.05）.
Conclusions 　The expression of SNCG is correlated with the cholangiocarcinoma occurrence， development， invasion， and metastasis. SNCG plays an important role in the infiltration and metastasis of carcinoma of bile duct. SNCG is expected to become a new cancer tumor marker， which can provide a basis to prognosize and to formulate the corres-
ponding therapy plan.

Citation： DAI Dongdong,LIU Guangwei,FENG Yujie,ZHANG Bingyuan,YIN Shuan,LU Yun.. Expression of γ-Synuclein Protein in Carcinoma of Bile Duct Tissues and Its Clinical Significance. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(4): 423-426. doi: Copy

1.	Bae WK， Shim HJ， Choi YD， et al. Severe hypothyroidism indu-ced by thyroid metastasis of cholangiocarcinoma[J]. Cancer ResTreat， 2009， 41(1)：56-58.
2.	宋振顺，范志勇，窦科峰，等. 肝门部胆管癌的诊断及治疗[J]. 中国实用外科杂志， 2009， 11(29)：966-968.
3.	Socoteanu MP， Mott F， Alpini G， et al. c-Met targeted therapy ofcholangiocarcinoma[J]. World J Gastroentero， 2008， 14(19)：2990-2994.
4.	杨晓洲，王勇，刘金钢. 细胞内信息传导与胆管癌的侵袭转移研究进展 [J]. 中国实用外科杂志， 2011， 31(6)：530-532.
5.	Ji H， Liu YE， Jia T， et al. Identification of a breast cancer-specific gene， BCSG1， by direct differential cDNA sequencing[J]. Cancer Res， 1997， 57(4)：759-764.
6.	Jia T， Liu YE， Liu J， et al. Stimulation of breast cancer invasion and metastasis by synuclein-γ[J]. Cancer Res， 1999， 59(3)：742-747.
7.	金琳芳，吴玉玉，陈进，等. SNCG、nm23在胃癌中的表达及临床意义[J]. 现代肿瘤医学， 2010， 18(11)：2196-2198.
8.	Sing VK， Jia Z. Targeting synuclein-gamma to counteract drug resistance in cancer[J]. Expert Opin Ther Targets， 2008， 12(1)：59-68.
9.	Bruening W， Giasson BI， Klein-Szanto AJ， et al. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary[J]. Cancer， 2000， 88(9)：2154-2163.
10.	Zhao W， Liu H， Liu W， et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration[J]. Int J Oncol， 2006， 28(5)：1081-1088.
11.	Li Z， Sclabas GM， Peng B， et al. Overexpression of synucleingamma in pancreatic adenocarcinoma[J]. Cancer， 2004， 101(1)：58-65.
12.	Wu K， Quan Z， Weng Z， et al. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis[J]. Breast Cancer Ras Treatmen， 2007， 101(3)：259-267.
13.	徐卫东，殷辉，赵建国，等. 原发性骨肉瘤中γ-Synuclein的表达[J]. 第二军医大学学报， 2007， 28(4)：432-435.
14.	Shaib YH， El-Serag HB， Davila JA， et al. Risk factors of intrahepatic cholangiocarcinoma in the United States：a case control study[J]. Gastroenterology， 2005， 128 (3)：620-626.
15.	Khan SA， Davidson BR， Goldin R， et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma：consensus document[J]. Gut， 2002， 51 Suppl 6：Ⅵ1-Ⅵ9.
16.	Khan SA， Thomas HC， Davidson BR， et al. Cholangiocarcinoma[J]. Lancet， 2005， 366(9493)：1303-1314.
17.	Liu XF， Zhou XT， Zou SQ. An analysis of 680 cases of cholangiocarcinoma from 8 hospitals [J]. Hepatobiliary Pancreat Dis Int， 2005， 4(4)：585-588.
18.	张惠卿，张宇新，张作风，等. γ-synuclein在乳腺癌中的表达及意义[J]. 中国肿瘤临床， 2005， 32(1)：9-12．.
19.	Yanagawa N， Tamura G， Honda L， et al. Demethylation of the synuclein gamma gene CpG island in primary gastric cancels and gastric cancers cell lines. CancerCell Lines[J]. Clin Cancer Res. 2004， 10(7)：2447-2451.
20.	Czekierdowski A， Czekierdowska S， Wielgos M， et al. The role of CpG islands hypomethylation and abnormal expression ofneuronal protein synuclein-gamma (SNCG) in ovarian cancer[J]. Neuro Endocrinol Lett， 2006， 27(3)：381-386.
21.	Iwaki H， Kageyama S， Isono T， et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin， gamma-synuclein， and catechol-o-methyltransferase) identified by proteomic analysis[J]. Cancer Sci， 2004， 95(12)：955-961.
22.	Liu H， Liu W， Wu Y， et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers[J]. Cancer Res， 2005， 65(17)：7635-7643.
23.	Hu H， Sun L， Guo C， et al. Tumor cell-microenvironment inter-action models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis[J]. Clin Cancer Res， 2009， 15(17)：5485-5493.
24.	Morgan J， Hoekstra AV， Chapman-Davis E， et al. Synuclein-γ(SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma[J]. Gynecol Oncol， 2009， 114(2)：293-298.
25.	Zhou CQ， Liu S， Xue LY， et al. Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma[J]. World J Gastroenterol， 2003， 9(9)：1900-1903.

1. Bae WK， Shim HJ， Choi YD， et al. Severe hypothyroidism indu-ced by thyroid metastasis of cholangiocarcinoma[J]. Cancer ResTreat， 2009， 41(1)：56-58.
2. 宋振顺，范志勇，窦科峰，等. 肝门部胆管癌的诊断及治疗[J]. 中国实用外科杂志， 2009， 11(29)：966-968.
3. Socoteanu MP， Mott F， Alpini G， et al. c-Met targeted therapy ofcholangiocarcinoma[J]. World J Gastroentero， 2008， 14(19)：2990-2994.
4. 杨晓洲，王勇，刘金钢. 细胞内信息传导与胆管癌的侵袭转移研究进展 [J]. 中国实用外科杂志， 2011， 31(6)：530-532.
5. Ji H， Liu YE， Jia T， et al. Identification of a breast cancer-specific gene， BCSG1， by direct differential cDNA sequencing[J]. Cancer Res， 1997， 57(4)：759-764.
6. Jia T， Liu YE， Liu J， et al. Stimulation of breast cancer invasion and metastasis by synuclein-γ[J]. Cancer Res， 1999， 59(3)：742-747.
7. 金琳芳，吴玉玉，陈进，等. SNCG、nm23在胃癌中的表达及临床意义[J]. 现代肿瘤医学， 2010， 18(11)：2196-2198.
8. Sing VK， Jia Z. Targeting synuclein-gamma to counteract drug resistance in cancer[J]. Expert Opin Ther Targets， 2008， 12(1)：59-68.
9. Bruening W， Giasson BI， Klein-Szanto AJ， et al. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary[J]. Cancer， 2000， 88(9)：2154-2163.
10. Zhao W， Liu H， Liu W， et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration[J]. Int J Oncol， 2006， 28(5)：1081-1088.
11. Li Z， Sclabas GM， Peng B， et al. Overexpression of synucleingamma in pancreatic adenocarcinoma[J]. Cancer， 2004， 101(1)：58-65.
12. Wu K， Quan Z， Weng Z， et al. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis[J]. Breast Cancer Ras Treatmen， 2007， 101(3)：259-267.
13. 徐卫东，殷辉，赵建国，等. 原发性骨肉瘤中γ-Synuclein的表达[J]. 第二军医大学学报， 2007， 28(4)：432-435.
14. Shaib YH， El-Serag HB， Davila JA， et al. Risk factors of intrahepatic cholangiocarcinoma in the United States：a case control study[J]. Gastroenterology， 2005， 128 (3)：620-626.
15. Khan SA， Davidson BR， Goldin R， et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma：consensus document[J]. Gut， 2002， 51 Suppl 6：Ⅵ1-Ⅵ9.
16. Khan SA， Thomas HC， Davidson BR， et al. Cholangiocarcinoma[J]. Lancet， 2005， 366(9493)：1303-1314.
17. Liu XF， Zhou XT， Zou SQ. An analysis of 680 cases of cholangiocarcinoma from 8 hospitals [J]. Hepatobiliary Pancreat Dis Int， 2005， 4(4)：585-588.
18. 张惠卿，张宇新，张作风，等. γ-synuclein在乳腺癌中的表达及意义[J]. 中国肿瘤临床， 2005， 32(1)：9-12．.
19. Yanagawa N， Tamura G， Honda L， et al. Demethylation of the synuclein gamma gene CpG island in primary gastric cancels and gastric cancers cell lines. CancerCell Lines[J]. Clin Cancer Res. 2004， 10(7)：2447-2451.
20. Czekierdowski A， Czekierdowska S， Wielgos M， et al. The role of CpG islands hypomethylation and abnormal expression ofneuronal protein synuclein-gamma (SNCG) in ovarian cancer[J]. Neuro Endocrinol Lett， 2006， 27(3)：381-386.
21. Iwaki H， Kageyama S， Isono T， et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin， gamma-synuclein， and catechol-o-methyltransferase) identified by proteomic analysis[J]. Cancer Sci， 2004， 95(12)：955-961.
22. Liu H， Liu W， Wu Y， et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers[J]. Cancer Res， 2005， 65(17)：7635-7643.
23. Hu H， Sun L， Guo C， et al. Tumor cell-microenvironment inter-action models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis[J]. Clin Cancer Res， 2009， 15(17)：5485-5493.
24. Morgan J， Hoekstra AV， Chapman-Davis E， et al. Synuclein-γ(SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma[J]. Gynecol Oncol， 2009， 114(2)：293-298.
25. Zhou CQ， Liu S， Xue LY， et al. Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma[J]. World J Gastroenterol， 2003， 9(9)：1900-1903.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of γ-Synuclein Protein in Carcinoma of Bile Duct Tissues and Its Clinical Significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content